DNER and small cell lung carcinoma: Another study similarly found that BET inhibitor I-BET762 combined with the PARP inhibitor talazoparib showed higher antitumoral activity in SCLC cells with elevated MYC expression or amplification of MYCs (Fiorentino et al., 2020).